Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Events & Webinars

BAUS 2023: When and how to treat prostate cancer?

Nubeqa Header Image

Treatment options in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone sensitive prostate cancer (mHSPC)

Description

In this Bayer sponsored webinar, as part of the BAUS ‘Innovations in Urology’ series, chair Mr Bill Cross, from Leeds Teaching Hospitals NHS Trust, is joined by experts to discuss the importance of developing multi-disciplinary approaches for the management of nmCRPC and mHSPC patients. Mr Cross leads the discussion by providing an overview of nmCRPC diagnosis and risk stratification. Exploring the clinical data on the use of first- and second-generation androgen receptor inhibitors (ARIs) as treatment options, Mr Cross provides a urologist’s perspective on how they can be used with standard care.

Ms Louisa Fleure, from Guy’s and St Thomas’ NHS Foundation Trust, describes the importance of patient-centred care when identifying and treating nmCRPC. By breaking down the goals of treatment, Ms Fleure examines the multi-disciplinary responsibilities when considering a care plan and a patient’s quality of life.

In the final section, Dr Vincent Khoo, from The Royal Marsden, examines the developments in metastatic hormone-sensitive prostate cancer (mHSPC) paradigms. Through the example of the ARASENS trial, Dr Khoo discusses the potential of combination therapy in metastatic cases.

The webinar concludes with an interactive Q&A chaired by Mr Cross addressing questions sent by the live audience.

This webinar is organised and funded by Bayer plc.

NUBEQA▼ Prescribing Information

 

Indication: NUBEQA is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease or metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.

Speakers
    • William CrossMr Bill Cross

    Mr Cross is a Consultant Urologist at Leeds Teaching Hospitals NHS Trust, with a specialist interest in prostate cancer. Bill is the clinical lead for prostate cancer and is actively involved in clinical and laboratory research and education. He currently sits on the trial management group of multiple prostate cancer trials including the STAMPEDE and RADICALS studies.

    • Louisa FleureMs Louisa Fleure

    Louisa Fleure is Urology Consultant Nurse at Guy’s and St Thomas’ NHS Trust, London. She has authored several publications on urology and prostate cancer and presented at regional, national and international meetings on these topics. Louisa has served as trustee for the British Association of Urological Nurses (BAUN) and held the posts of Secretary, Treasurer and Conference Lead. Louisa’s hard work and dedication in the field of advanced prostate cancer has been widely acknowledged and has included: the Lynn Adams Award for leadership and innovation in cancer nursing (2014), runner up in the BJN urology nurse of the year (2015), 2016 BAUN Urology Team of the Year, finalist in oncology quality in Care Awards: prostate cancer survivorship team (2016), and the Nightingale Award (2018).

     

    Louisa Fleure was awarded The Urology Foundation/BAUN’s ‘Urology Nurse of the Year’ award in November 2019 for her work in providing information and support to men with advanced prostate cancer.

     

    Louisa is chair of the prostate Special Interest Group for the European Association of Urological Nurses.

    • dr-vincent-khooDr Vincent Khoo

    Vincent Khoo is a Consultant in Clinical Oncology at The Royal Marsden and Honorary Consultant at St George's University Hospitals NHS Foundation Trust as well as Honorary Reader at The Institute of Cancer Research, University of London; Adjunct Professor at Monash University, Melbourne and Associate Professor at University of Melbourne. After qualifying in medicine in 1985, Vincent trained and worked in clinical oncology in the UK, USA and Australia, and leads collaborative research groups in the UK and Australia. Specialising in urological cancers, he is Clinical Lead, Clinical Trials Unit Urology Chelsea (CTUUC), at The Royal Marsden’s Chelsea branch and offers a comprehensive array of therapies, including systemic therapies such as hormonal, targeted therapies and chemotherapy.

BAUN 2022
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1314, February 2024
BAUS 2022: Navigating treatment decisions in nmCRPC patients
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1298, February 2024
BAUS 2023: The role of Urologists in the MDT
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1319, February 2024

PP-NUB-GB-1300 | February 2024